A retrospective study in SKT11 mutated lung cancer patients (developed hyperprogressive disease) to assess outcomes when given Immune checkpoint inhibitors
Latest Information Update: 17 Jun 2020
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 17 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology